Time point | Screening | Adjuvant chemotherapy | Close-out | |||
---|---|---|---|---|---|---|
− t1–0 | t1 | t2 | t3 | t4 | t5–tx | |
Enrollment | ||||||
 Screening | X |  |  |  |  |  |
 Informed consent | X |  |  |  |  |  |
Program | ||||||
 Cohort 1 (ATO + P) | X | X | X | X | X | X |
 Cohort 1 (T + P) | X | X | X | X | X | X |
Assessment | ||||||
 Patients characteristic | X |  |  |  |  |  |
 Medical history | X |  |  |  |  |  |
 Performance status | X |  |  |  |  |  |
 Karnofsky | X |  |  |  |  |  |
 Blood test |  | X | X | X | X | X |
 Liver function test |  | X | X | X | X | X |
 Kidney function test |  | X | X | X | X | X |
 Color Doppler ultrasound |  | X |  | X |  | X |
 Tumor markers |  | X |  | X |  | X |
 Imaging examination (MRI) |  | X |  |  |  | X |
 RECIST |  |  |  |  |  | X |
 CTCAE |  |  |  |  |  | X |
Cohort migration | Â | Â | Â | Â | Â | X |
Combined medication | Â | Â | Â | Â | Â | X |